Molecular mechanisms and cell targets of Th17 cells in the gastrointestinal tract: An innate sense of adaptivity

International Reviews of Immunology

Volumn 32, Issue 5-6, 2013, Pages 475-492

  Verdier, Julien ^a,b,c   Ruemmele, Frank M ^a,b,d  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Act1; Colitis; IL 17 receptor; Inflammatory bowel diseases; SEFIR; Signaling; Th17

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 17B; INTERLEUKIN 17C; INTERLEUKIN 17F; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 25; INTERLEUKIN 26; INTERLEUKIN 27; MESSENGER RNA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; DIGESTIVE SYSTEM INFLAMMATION; GASTROINTESTINAL TRACT; HEMATOPOIETIC CELL; HUMAN; INTESTINE CELL; INTESTINE EPITHELIUM CELL; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TARGET CELL; TH17 CELL;

ADAPTIVE IMMUNITY; ANIMALS; CELL COMMUNICATION; CYTOKINES; GASTROINTESTINAL TRACT; HUMANS; IMMUNITY, INNATE; SIGNAL TRANSDUCTION; TH17 CELLS;

EID: 84887389505     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830185.2013.829471     Document Type: Review

References (196)

1. Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 2007;449(7164):819-826.
2. McGeachy MJ, Chen Y, Tato CM, et al. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol 2009;10(3):314-324.
3. Ghoreschi K, Laurence A, Yang XP, et al. Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling. Nature 2010;467(7318):967-971.
4. Hernandez-Santos N, Gaffen SL. Th17 cells in immunity to Candida albicans. Cell Host Microbe 2012;11(5):425-435.
5. Puel A, Cypowyj S, Bustamante J, et al. Chronicmucocutaneous candidiasis in humanswith inborn errors of interleukin-17 immunity. Science 2011;332(6025):65-68.
6. Puel A, Cypowyj S,Marodi L, et al. Inborn errors of human IL-17 immunity underlie chronicmucocutaneous candidiasis. Curr Opin Allergy Clin Immunol 2012;12(6):616-622.
7. McDonald DR. TH17 deficiency in human disease. J Allergy Clin Immunol 2012;129(6):1429-1435; quiz 1436-1437.
8. Fouser LA, Wright JF,Dunussi-Joannopoulos K, Collins M. Th17 cytokines and their emerging roles in inflammation and autoimmunity. Immunol Rev 2008;226:87-102.
9. Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol 2010;28:573-621.
10. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006;314(5804):1461-1463.
11. Glas J, Seiderer J,Wetzke M, et al. rs1004819 is themain disease-associated IL23R variant inGerman Crohn's disease patients: combined analysis of IL23R, CARD15, and OCTN1/2 variants. PLoS One 2007;2(9):e819.
12. Momozawa Y, Mni M, Nakamura K, et al. Resequencing of positional candidates identifies low frequency IL23R coding variants protecting against inflammatory bowel disease. Nat Genet 2011;43(1):43-47.
13. Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008;40(8):955-962.
14. Fisher SA, Tremelling M, Anderson CA, et al. Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. Nat Genet 2008;40(6):710-712.
15. Franke A, Balschun T,Karlsen TH, et al. Replication of signals fromrecent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis. Nat Genet 2008;40(6):713-715.
16. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011;474(7351):307-317.
17. Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci TranslMed 2010;2(52):52ra72.
18. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl JMed 2012;366(13):1190-1199.
19. Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17- receptor antibody for psoriasis. N Engl JMed 2012;366(13):1181-1189.
20. Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov 2012;11(10):763-776.
21. Garber K. Anti-IL-17 mAbs herald new options in psoriasis. Nat Biotechnol 2012;30(6):475-477.
22. Patel DD, Lee DM, Kolbinger F, Antoni C. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis 2013;72(Suppl 2):ii116-ii123.
23. Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, formoderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebocontrolled trial. Gut 2012;61(12):1693- 1700.
24. Symons A, Budelsky AL, Towne JE. Are Th17 cells in the gut pathogenic or protective?Mucosal Immunol 2012;5(1):4-6.
25. Vermeire S, Rutgeerts P. IBD in 2012: Pathogenesis andmanagement of IBD-thinking outside the box. Nat Rev Gastroenterol Hepatol 2013;10(2):67-69.
26. Ivanov, II, Frutos Rde L, Manel N, et al. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in themucosa of the small intestine. Cell HostMicrobe 2008;4(4):337-49.
27. Littman DR, Rudensky AY.Th17 and regulatory T cells in mediating and restraining inflammation. Cell 2010;140(6):845-858.
28. Gaboriau-Routhiau V, Rakotobe S, Lecuyer E, et al.Thekey role of segmented filamentous bacteria in the coordinatedmaturation of gut helper T cell responses. Immunity 2009;31(4):677-689.
29. Ivanov, II, Atarashi K, Manel N, et al. Induction of intestinalTh17 cells by segmented filamentous bacteria. Cell 2009;139(3):485-498.
30. Roberts S, Gueguen Y, de Lorgeril J, Goetz F. Rapid accumulation of an interleukin 17 homolog transcript in Crassostrea gigas hemocytes following bacterial exposure.Dev Comp Immunol 2008;32(9):1099-1104.
31. Guo P, HiranoM, Herrin BR, et al. Dual nature of the adaptive immune system in lampreys. Nature 2009;459(7248):796-801.
32. Secombes CJ,Wang T, Bird S. The interleukins of fish. Dev Comp Immunol 2011;35(12):1336-1345.
33. Wu B, Jin M, Zhang Y, et al. Evolution of the IL17 receptor family in chordates: a new subfamily IL17REL. Immunogenetics 2011;63(12):835-845.
34. Eberl G. Development and evolution of RORgammat+ cells in a microbe's world. Immunol Rev 2012;245(1):177-188.
35. Moseley TA, Haudenschild DR, Rose L, Reddi AH. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 2003;14(2):155-174.
36. Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity 2004;21(4):467-476.
37. Yao Z, Fanslow WC, Seldin MF, et al. Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 1995;3(6):811-821.
38. Yao Z, Spriggs MK, Derry JM, et al. Molecular characterization of the human interleukin (IL)-17 receptor. Cytokine 1997;9(11):794-800.
39. Iwakura Y, Ishigame H, Saijo S, Nakae S. Functional specialization of interleukin-17 family members. Immunity 2011;34(2):149-162.
40. Song X, Qian Y. The activation and regulation of IL-17 receptor mediated signaling. Cytokine 2013;62(2):175-182.
41. Li H, Chen J, Huang A, et al. Cloning and characterization of IL-17B and IL-17C, two newmembers of the IL-17 cytokine family. Proc Natl Acad Sci USA 2000;97(2):773-778.
42. Yamaguchi Y, Fujio K, Shoda H, et al. IL-17B and IL-17C are associated with TNF-alpha production and contribute to the exacerbation of inflammatory arthritis. J Immunol 2007;179(10):7128-7136.
43. Hymowitz SG, Filvaroff EH, Yin JP, et al. IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding. EMBO J 2001;20(19):5332-5341.
44. Starnes T, Robertson MJ, SledgeG, et al. Cutting edge: IL-17F, a novel cytokine selectively expressed in activated T cells and monocytes, regulates angiogenesis and endothelial cell cytokine production. J Immunol 2001;167(8):4137-4140.
45. Yang XO, Chang SH, Park H, et al. Regulation of inflammatory responses by IL-17F. J Exp Med 2008;205(5):1063-1075.
46. Gomez-Rodriguez J, SahuN,Handon R, et al. Differential expression of interleukin-17A and-17F is coupled to T cell receptor signaling via inducible T cell kinase. Immunity 2009;31(4):587-597.
47. Hedrich CM, Rauen T, Kis-Toth K, et al. cAMP-responsive element modulator alpha (CREMalpha) suppresses IL-17F protein expression in T lymphocytes from patients with systemic lupus erythematosus (SLE). J Biol Chem 2012;287(7):4715-4725.
48. ToyD, KuglerD,Wolfson M, et al. Cutting edge: interleukin 17 signals through a heteromeric receptor complex. J Immunol 2006;177(1):36-39.
49. Ely LK, Fischer S, Garcia KC. Structural basis of receptor sharing by interleukin 17 cytokines. Nat Immunol 2009;10(12):1245-1251.
50. Liu S, Song X, Chrunyk BA, et al. Crystal structures of interleukin 17A and its complex with IL-17 receptor A. Nat Commun 2013;4:1888.
51. Shen F, Gaffen SL. Structure-function relationships in the IL-17 receptor: implications for signal transduction and therapy. Cytokine 2008;41(2):92-104.
52. Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 2009;9(8):556-567.
53. Onishi RM, Park SJ, Hanel W, et al. SEF/IL-17R (SEFIR) is not enough: an extended SEFIR domain is required for il-17RA-mediated signal transduction. J Biol Chem 2010;285(43):32751-9.
54. Leonard WJ, O'Shea JJ. Jaks and STATs: biological implications. Annu Rev Immunol 1998;16:293-322.
55. Murray PJ.The JAK-STAT signaling pathway: input and output integration. J Immunol 2007;178(5): 2623-2629.
56. Shalom-Barak T, Quach J, Lotz M. Interleukin-17-induced gene expression in articular chondrocytes is associatedwith activation of mitogen- activatedprotein kinases andNF-kappaB. JBiolChem 1998;273(42):27467-27473.
57. AwaneM, Andres PG, Li DJ, Reinecker HC. NF-kappa B-inducing kinase is a common mediator of IL-17-, TNF-alpha-, and IL-1 beta-induced chemokine promoter activation in intestinal epithelial cells. J Immunol 1999;162(9):5337-5344.
58. Schwandner R, Yamaguchi K, Cao Z. Requirement of tumor necrosis factor receptor-associated factor (TRAF)6 in interleukin 17 signal transduction. J ExpMed 2000;191(7):1233-1240.
59. Ruddy MJ, Wong GC, Liu XK, et al. Functional cooperation between interleukin-17 and tumor necrosis factor-alpha is mediated by CCAAT/enhancer-binding protein family members. J Biol Chem 2004;279(4):2559- 2567.
60. Shen F, Hu Z, Goswami J, Gaffen SL. Identification of common transcriptional regulatory elements in interleukin-17 target genes. J Biol Chem 2006;281(34):24138-24148.
61. Yamazaki S, Muta T, Matsuo S, Takeshige K. Stimulus-specific induction of a novel nuclear factorkappaB regulator, IkappaB-zeta, via Toll/Interleukin-1 receptor is mediated bymRNA stabilization. J Biol Chem 2005;280(2):1678-1687.
62. Shen F, Ruddy MJ, Plamondon P, Gaffen SL. Cytokines link osteoblasts and inflammation: microarray analysis of interleukin-17-and TNF-alpha-induced genes in bone cells. J Leukoc Biol 2005;77(3):388-399.
63. Novatchkova M, Leibbrandt A, Werzowa J, et al.The STIR-domain superfamily in signal transduction, development and immunity. Trends Biochem Sci 2003;28(5):226-229.
64. Chang SH,Park H,Dong C.Act1 adaptor protein is an immediate andessential signalingcomponent of interleukin-17 receptor. J Biol Chem 2006;281(47):35603- 35607.
65. Qian Y, Liu C,Hartupee J, et al.Theadaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease. Nat Immunol 2007;8(3):247-256.
66. Linden A. A role for the cytoplasmic adaptor protein Act1 in mediating IL-17 signaling. Sci STKE 2007;2007(398):re4.
67. Sonder SU, Saret S, Tang W, et al. IL-17-induced NF-kappaB activation via CIKS/Act1: physiologic significance and signaling mechanisms. J Biol Chem 2011;286(15):12881-12890.
68. Liu C, Qian W, Qian Y, et al. Act1, a U-box E3 ubiquitin ligase for IL-17 signaling. Sci Signal 2009;2(92):ra63.
69. Hartupee J, Liu C, Novotny M, et al. IL-17 enhances chemokine gene expression through mRNA stabilization. J Immunol 2007;179(6):4135-4141.
70. Hartupee J, Liu C, Novotny M, et al. IL-17 signaling for mRNA stabilization does not require TNF receptor-associated factor 6. J Immunol 2009;182(3):1660-1666.
71. Bulek K, Liu C, Swaidani S, et al. The inducible kinase IKKi is required for IL-17-dependent signaling associated with neutrophilia and pulmonary inflammation. Nat Immunol 2011;12(9): 844-852.
72. Sun D, Novotny M, Bulek K, et al. Treatment with IL-17 prolongs the half-life of chemokine CXCL1 mRNA via the adaptor TRAF5 and the splicing-regulatory factor SF2 (ASF). Nat Immunol 2011; 12(9):853-860.
73. Zhu S, Pan W, Song X, et al.The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-alpha. NatMed 2012;18(7):1077-1086.
74. Shi P, Zhu S, Lin Y, et al. Persistent stimulation with interleukin-17 desensitizes cells through SCFbeta-TrCP-mediated degradation of Act1. Sci Signal 2011;4(197):ra73.
75. Garg AV, Ahmed M, Vallejo AN, et al. The deubiquitinase a20 mediates feedback inhibition of interleukin-17 receptor signaling. Sci Signal 2013;6(278):ra44.
76. Spolski R, Leonard WJ. Cytokinemediators of Th17 function. Eur J Immunol 2009;39(3):658-661.
77. Nakayamada S, Takahashi H, Kanno Y, O'Shea JJ. Helper T cell diversity and plasticity. Curr Opin Immunol 2012;24(3):297-302.
78. Zhou L, Ivanov, II, Spolski R, et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007;8(9):967-974.
79. Korn T, Bettelli E, Gao W, et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007;448(7152):484-487.
80. Nurieva R, Yang XO, Martinez G, et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007;448(7152):480-483.
81. Wei L, Laurence A, Elias KM, O'Shea JJ. IL-21 is produced byTh17 cells and drives IL-17 production in a STAT3-dependentmanner. J Biol Chem 2007;282(48):34605-34610.
82. Yamane H, Paul WE.Cytokines of the gamma(c) family controlCD4+T cell differentiation and function. Nat Immunol 2012;13(11):1037-1044.
83. Suto A, Kashiwakuma D, Kagami S, et al. Development and characterization of IL-21-producing CD4+ T cells. J ExpMed 2008;205(6):1369-1379.
84. Sarra M, Monteleone I, Stolfi C, et al. Interferon-gamma-expressing cells are a major source of interleukin-21 in inflammatory bowel diseases. Inflamm Bowel Dis 2010;16(8):1332-1339.
85. De Nitto D, Sarra M, Pallone F,Monteleone G. Interleukin-21 triggers effector cell responses in the gut.World J Gastroenterol 2010;16(29):3638-3641.
86. Liang SC, Tan XY, Luxenberg DP, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006;203(10): 2271-2279.
87. Chung Y, Yang X, Chang SH, et al. Expression and regulation of IL-22 in the IL-17-producing CD4+ T lymphocytes. Cell Res 2006;16(11):902-907.
88. Zheng Y,DanilenkoDM, Valdez P, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007;445(7128):648-651.
89. Ouyang W, Rutz S, Crellin NK, et al. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol 2011;29:71-109.
90. Lejeune D, Dumoutier L, Constantinescu S, et al. Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct fromIL-10. J Biol Chem 2002;277(37):33676-33682.
91. Wolk K, Kunz S, Witte E, et al. IL-22 increases the innate immunity of tissues. Immunity 2004;21(2):241-54.
92. Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007;8(9):950-957.
93. Donnelly RP, Sheikh F, Dickensheets H, et al. Interleukin-26: an IL-10-related cytokine produced by Th17 cells. Cytokine Growth Factor Rev 2010;21(5):393-401.
94. Sheikh F, Baurin VV, Lewis-Antes A, et al. Cutting edge: IL-26 signals through a novel receptor complex composed of IL-20 receptor 1 and IL-10 receptor 2. J Immunol 2004;172(4):2006-2010.
95. Hor S, Pirzer H, Dumoutier L, et al. The T-cell lymphokine interleukin-26 targets epithelial cells through the interleukin-20 receptor 1 and interleukin-10 receptor 2 chains. J Biol Chem 2004;279(32):33343-33351.
96. Raffatellu M, Santos RL, Verhoeven DE, et al. Simian immunodeficiency virus-induced mucosal interleukin-17 deficiency promotes Salmonella dissemination from the gut. Nat Med 2008;14(4): 421-428.
97. Dambacher J, Beigel F, Zitzmann K, et al. The role of the novel Th17 cytokine IL-26 in intestinal inflammation. Gut 2009;58(9):1207-1217.
98. Fossiez F,DjossouO,Chomarat P, et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J ExpMed 1996;183(6):2593-2603.
99. Zheng Y, Valdez PA, DanilenkoDM, et al. Interleukin-22mediates early host defense against attaching and effacing bacterial pathogens. NatMed 2008;14(3):282-289.
100. Onishi RM, Gaffen SL. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology 2010;129(3):311-321.
101. Ye P, Rodriguez FH, Kanaly S, et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression,neutrophil recruitment, and host defense. J ExpMed 2001;194(4):519-527.
102. Fournier BM, Parkos CA.Therole of neutrophils during intestinal inflammation.MucosalImmunol 2012;5(4):354-366.
103. Moss AJ, Ryan D, Oakes D, et al. Atherosclerotic risk genotypes and recurrent coronary events after myocardial infarction. Am J Cardiol 2005;96(2):177-182.
104. Lubberts E, Schwarzenberger P, Huang W, et al. Requirement of IL-17 receptor signaling in radiation-resistant cells in the joint for full progression of destructive synovitis. J Immunol 2005;175(5):3360-3368.
105. Chang SH, Dong C. Signaling of interleukin-17 family cytokines in immunity and inflammation. Cell Signal 2011;23(7):1069-1075.
106. Conti HR, Shen F, Nayyar N, et al.Th17 cells and IL-17 receptor signaling are essential formucosal host defense against oral candidiasis. J ExpMed 2009;206(2):299-311.
107. Medina C, RadomskiMW. Role ofmatrix metalloproteinases in intestinal inflammation. J Pharmacol ExpTher 2006;318(3):933-938.
108. Miljkovic D, Trajkovic V. Inducible nitric oxide synthase activation by interleukin-17. Cytokine Growth Factor Rev 2004;15(1):21-32.
109. TakahashiN,Vanlaere I, deRycke R, et al. IL-17 produced byPaneth cells drivesTNF-induced shock. J ExpMed 2008;205(8):1755-1761.
110. Zhang Y,Wang H, Ren J, et al. IL-17A synergizes with IFN-gamma to upregulate iNOS and NO production and inhibit chlamydial growth. PLoS One 2012;7(6):e39214.
111. Kolios G, Valatas V,Ward SG. Nitric oxide in inflammatory bowel disease: a universal messenger in an unsolved puzzle. Immunology 2004;113(4):427-437.
112. Lundberg JO, Weitzberg E. Biology of nitrogen oxides in the gastrointestinal tract. Gut 2013;62(4):616-629.
113. Ishigame H, Kakuta S, Nagai T, et al. Differential roles of interleukin-17A and-17F in host defense againstmucoepithelial bacterial infection and allergic responses. Immunity 2009;30(1):108-119.
114. Rubino SJ, Geddes K, Girardin SE. Innate IL-17 and IL-22 responses to enteric bacterial pathogens. Trends Immunol 2012;33(3):112-118.
115. Kinugasa T, Sakaguchi T, Gu X, Reinecker HC. Claudins regulate the intestinal barrier in response to immune mediators. Gastroenterology 2000;118(6):1001-1011.
116. Liu JZ, Pezeshki M, Raffatellu M. Th17 cytokines and host-pathogen interactions at the mucosa: dichotomies of help and harm. Cytokine 2009;48(1-2):156-60.
117. Blaschitz C, Raffatellu M. Th17 cytokines and the gut mucosal barrier. J Clin Immunol 2010;30(2):196-203.
118. Menard S, Cerf-Bensussan N, Heyman M. Multiple facets of intestinal permeability and epithelial handling of dietary antigens.Mucosal Immunol 2010;3(3):247-259.
119. Suzuki T. Regulation of intestinal epithelial permeability by tight junctions. Cell Mol Life Sci 2013;70(4):631-659.
120. Kebir H, Kreymborg K, Ifergan I, et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. NatMed 2007;13(10):1173-1175.
121. Schwartz S, Beaulieu JF, Ruemmele FM. Interleukin-17 is a potent immuno-modulator and regulator of normal human intestinal epithelial cell growth. Biochem Biophys Res Commun 2005;337(2):505-509.
122. Sparna T, Retey J, Schmich K, et al. Genome-wide comparison between IL-17 and combined TNFalpha/ IL-17 induced genes in primarymurine hepatocytes. BMC Genomics 2010;11:226.
123. Chiricozzi A, Guttman-Yassky E, Suarez-Farinas M, et al. Integrative responses to IL-17 and TNFalpha inhuman keratinocytes account for key inflammatory pathogenic circuits inpsoriasis. J Invest Dermatol 2011;131(3):677-687.
124. Lee JW,Wang P, Kattah MG, et al. Differential regulation of chemokines by IL-17 in colonic epithelial cells. J Immunol 2008;181(9):6536-6545.
125. Zepp J,Wu L, Li X. IL-17 receptor signaling and T helper 17-mediated autoimmune demyelinating disease. Trends Immunol 2011;32(5):232-239.
126. Ogawa A, Andoh A, Araki Y, et al. Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. Clin Immunol 2004;110(1):55-62.
127. Cao AT, Yao S, Gong B, et al. Th17 cells upregulate polymeric Ig receptor and intestinal IgA and contribute to intestinal homeostasis. J Immunol 2012;189(9):4666-4673.
128. Ramirez-Carrozzi V, Sambandam A, Luis E, et al. IL-17C regulates the innate immune function of epithelial cells in an autocrinemanner. Nat Immunol 2011;12(12):1159-1166.
129. Reynolds JM,MartinezGJ,Nallaparaju KC, et al. Cutting edge: regulation of intestinal inflammation and barrier function by IL-17C. J Immunol 2012;189(9):4226-4230.
130. Owyang AM, Zaph C, Wilson EH, et al. Interleukin 25 regulates type 2 cytokine-dependent immunity and limits chronic inflammation in the gastrointestinal tract. J Exp Med 2006;203(4): 843-849.
131. Hot A, Zrioual S, Toh ML, et al. IL-17A-versus IL-17F-induced intracellular signal transduction pathways and modulation by IL-17RA and IL-17RC RNA interference in rheumatoid synoviocytes. Ann Rheum Dis 2011;70(2):341-348.
132. Hot A,Miossec P. Effects of interleukin (IL)-17A and IL-17F in human rheumatoid arthritis synoviocytes. Ann Rheum Dis 2011;70(5):727-732.
133. Pabst O. New concepts in the generation and functions of IgA. Nat Rev Immunol 2012;12(12): 821-832.
134. Aujla SJ, Chan YR, ZhengM, et al. IL-22mediatesmucosal host defense againstGram-negative bacterial pneumonia. NatMed 2008;14(3):275-281.
135. Jaffar Z, Ferrini ME, Herritt LA, Roberts K. Cutting edge: lung mucosal Th17-mediated responses induce polymeric Ig receptor expression by the airway epithelium and elevate secretory IgA levels. J Immunol 2009;182(8):4507-4511.
136. Moisan J, Grenningloh R, Bettelli E, et al. Ets-1 is a negative regulator of Th17 differentiation. J Exp Med 2007;204(12):2825-2835.
137. Chen Y,Thai P, Zhao YH, et al. Stimulation of airwaymucin gene expression by interleukin (IL)-17 through IL-6 paracrine/autocrine loop. J Biol Chem 2003;278(19):17036-17043.
138. Kallal LE,Hartigan AJ,Hogaboam CM, et al. Inefficient lymph node sensitization during respiratory viral infection promotes IL-17-mediated lung pathology. J Immunol 2010;185(7):4137-4147.
139. BystromJ, Al-AdhoubiN, Al-Bogami M, et al.Th17 lymphocytes in respiratory syncytial virus infection. Viruses 2013;5(3):777-791.
140. McGuckin MA, Linden SK, Sutton P, Florin TH. Mucin dynamics and enteric pathogens. Nat Rev Microbiol 2011;9(4):265-278.
141. Johansson ME, Sjovall H, Hansson GC. The gastrointestinal mucus system in health and disease. Nat Rev Gastroenterol Hepatol 2013;10:352-361.
142. Franke A,McGovern DP, Barrett JC, et al. Genome-widemeta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010;42(12):1118-1125.
143. Hooper LV, Wong MH, Thelin A, et al. Molecular analysis of commensal host-microbial relationships in the intestine. Science 2001;291(5505):881-884.
144. Sommer F, Backhed F. The gut microbiota-masters of host development and physiology. Nat Rev Microbiol 2013;11(4):227-238.
145. Sugimoto K, Ogawa A, Mizoguchi E, et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest 2008;118(2):534-544.
146. ChaHR,Chang SY,Chang JH, et al.Downregulation ofTh17 cells in thesmall intestine by disruption of gut flora in the absence of retinoic acid. J Immunol 2010;184(12):6799-6806.
147. Kuestner RE, Taft DW, Haran A, et al. Identification of the IL-17 receptor related molecule IL-17RC as the receptor for IL-17F. J Immunol 2007;179(8):5462-5473.
148. Jovanovic DV, Di Battista JA, Martel-Pelletier J, et al. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol 1998;160(7):3513-3521.
149. Feng T, QinH,Wang L, et al. Th17 cells induce colitis and promoteTh1cell responses through IL-17 induction of innate IL-12 and IL-23 production. J Immunol 2011;186(11):6313-6318.
150. Lin Y, Ritchea S, Logar A, et al. Interleukin-17 is required for T helper 1 cell immunity and host resistance to the intracellular pathogen Francisella tularensis. Immunity 2009;31(5): 799-810.
151. O'Connor W, Jr., Kamanaka M, Booth CJ, et al. A protective function for interleukin 17A in T cellmediated intestinal inflammation. Nat Immunol 2009;10(6):603-609.
152. Nakae S, Komiyama Y, Nambu A, et al. Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity 2002;17(3):375-387.
153. Hsu HC, Yang P, Wang J, et al. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol 2008;9(2):166-175.
154. Doreau A, Belot A, Bastid J, et al. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol 2009;10(7):778-785.
155. Mitsdoerffer M, Lee Y, Jager A, et al. Proinflammatory T helper type 17 cells are effective B-cell helpers. Proc Natl Acad Sci USA 2010;107(32):14292- 14297.
156. Sweet RA, Lee SK, Vinuesa CG. Developing connections amongst key cytokines and dysregulated germinal centers in autoimmunity. Curr Opin Immunol 2012;24(6):658-664.
157. Qian Y, Qin J, Cui G, et al. Act1, a negative regulator in CD40-and BAFF-mediated B cell survival. Immunity 2004;21(4):575-587.
158. Pisitkun P, Ha HL,Wang H, et al. Interleukin-17 cytokines are critical in development of fatal lupus glomerulonephritis. Immunity 2012;37(6):1104-1115.
159. Grogan JL, Ouyang W. A role for Th17 cells in the regulation of tertiary lymphoid follicles. Eur J Immunol 2012;42(9):2255-2262.
160. Aloisi F, Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases.Nat Rev Immunol 2006;6(3):205-217.
161. van de Pavert SA,Mebius RE. New insights into the development of lymphoid tissues. Nat Rev Immunol 2010;10(9):664-674.
162. Peters A, Pitcher LA, Sullivan JM, et al.Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation. Immunity 2011;35(6):986-996.
163. Eberl G, Lochner M. The development of intestinal lymphoid tissues at the interface of self and microbiota.Mucosal Immunol 2009;2(6):478-485.
164. Pearson C,Uhlig HH, Powrie F. Lymphoid microenvironments and innate lymphoid cells in the gut. Trends Immunol 2012;33(6):289-296.
165. Lochner M, Ohnmacht C, Presley L, et al. Microbiota-induced tertiary lymphoid tissues aggravate inflammatory disease in the absence of RORgamma t and LTi cells. J Exp Med 2011;208(1): 125-134.
166. Rangel-Moreno J, Carragher DM, de la Luz Garcia-Hernandez M, et al. The development of inducible bronchus-associated lymphoid tissue depends on IL-17. Nat Immunol 2011;12(7):639-646.
167. Bermejo DA, Jackson SW, Gorosito-Serran M, et al. Trypanosoma cruzi trans-sialidase initiates a programindependent of the transcription factors RORgammat and Ahr that leads to IL-17 production by activated B cells. Nat Immunol 2013;14(5):514-522.
168. Raffatellu M, George MD, Akiyama Y, et al. Lipocalin-2 resistance confers an advantage to Salmonella enterica serotype Typhimurium for growth and survival in the inflamed intestine. Cell HostMicrobe 2009;5(5):476-486.
169. Zenewicz LA, Yancopoulos GD, Valenzuela DM, et al. Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity 2008;29(6):947-957.
170. Pickert G, Neufert C, Leppkes M, et al. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J ExpMed 2009;206(7):1465-1472.
171. Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl JMed 2009;361(21):2033-2045.
172. Begue B, Verdier J, Rieux-Laucat F, et al. Defective IL10 signaling defining a subgroup of patients with inflammatory bowel disease. Am J Gastroenterol 2011;106(8):1544-1555.
173. Kotlarz D, Beier R, Murugan D, et al. Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy. Gastroenterology 2012;143(2):347-355.
174. Engelhardt KR, Shah N, Faizura-Yeop I, et al. Clinical outcome in IL-10-and IL-10 receptordeficient patients with or without hematopoietic stem cell transplantation. J Allergy Clin Immunol 2013;131(3):825-830.
175. Shah N,Kammermeier J, ElawadM,Glocker EO. Interleukin-10 and interleukin-10-receptor defects in inflammatory bowel disease. Curr Allergy Asthma Rep 2012;12(5):373-379.
176. Sonnenberg GF, Nair MG, Kirn TJ, et al. Pathological versus protective functions of IL-22 in airway inflammation are regulated by IL-17A. J ExpMed 2010;207(6):1293-1305.
177. Mundy R,MacDonald TT, Dougan G, et al. Citrobacter rodentium ofmice andman. CellMicrobiol 2005;7(12):1697-1706.
178. Sonnenberg GF, Monticelli LA, Elloso MM, et al. CD4(+) lymphoid tissue-inducer cells promote innate immunity in the gut. Immunity 2011;34(1):122-134.
179. SonnenbergGF, ArtisD. Innate lymphoid cell interactionswithmicrobiota: implications for intestinal health and disease. Immunity 2012;37(4):601-610.
180. Spits H, Di Santo JP.The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling. Nat Immunol 2011;12(1):21-27.
181. Sonnenberg GF, Monticelli LA, Alenghat T, et al. Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria. Science 2012;336(6086):1321-1325.
182. Basu R, O'Quinn DB, Silberger DJ, et al.Th22 cells are an important source of IL-22 for host protection against enteropathogenic bacteria. Immunity 2012 37(6):1061-1075.
183. von Vietinghoff S, Ley K. IL-17A controls IL-17F production andmaintains blood neutrophil counts in mice. J Immunol 2009;183(2):865-873.
184. Kanai T, Mikami Y, Sujino T, et al. RORgammat-dependent IL-17A-producing cells in the pathogenesis of intestinal inflammation.Mucosal Immunol 2012;5(3):240-247.
185. Izcue A, Hue S, Buonocore S, et al. Interleukin-23 restrains regulatory T cell activity to drive T celldependent colitis. Immunity 2008;28(4):559-570.
186. Ahern PP, Schiering C, Buonocore S, et al. Interleukin-23 drives intestinal inflammation through direct activity on T cells. Immunity 2010;33(2):279-288.
187. Liu Z, Feng BS, Yang SB, et al. Interleukin (IL)-23 suppresses IL-10 in inflammatory bowel disease. J Biol Chem 2012;287(5):3591-3597.
188. Intlekofer AM, Banerjee A, Takemoto N, et al. Anomalous type 17 response to viral infection by CD8+ T cells lacking T-bet and eomesodermin. Science 2008;321(5887):408-411.
189. Huber S, Gagliani N, Zenewicz LA, et al. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature 2012;491(7423):259-263.
190. Sutton CE, Mielke LA, Mills KH. IL-17-producing gammadelta T cells and innate lymphoid cells. Eur J Immunol 2012;42(9):2221-2231.
191. Cua DJ, Tato CM. Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol 2010;10(7):479-489.
192. Michel ML, Keller AC, PagetC, et al. Identification of an IL-17-producing NK1.1(neg) iNKT cell population involved in airway neutrophilia. J ExpMed 2007;204(5):995-1001.
193. Hueber AJ, AsquithDL,MillerAM, et al.Mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol 2010;184(7):3336-3340.
194. Lin AM, Rubin CJ, Khandpur R, et al.Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol 2011;187(1):490-500.
195. Li L,Huang L, Vergis AL, et al. IL-17 produced by neutrophils regulates IFN-gamma-mediated neutrophil migration inmouse kidney ischemia-reperfusion injury. J Clin Invest 2010;120(1):331-342.
196. Werner JL, Gessner MA, Lilly LM, et al. Neutrophils produce interleukin 17A (IL-17A) in a dectin-1-and IL-23-dependent manner during invasive fungal infection. Infect Immun 2011;79(10):3966-3977.